• Hyperhomocysteinemia HHcy is a clinical condition characteri

  2022-04-02

  

  Hyperhomocysteinemia (HHcy) is a clinical condition characterized by increased levels of plasma homocysteine (Hcy) and a well-known risk factor for CVDs. Hcy is a sulfur-containing non-protein amino Diclofenac Sodium formed during the intracellular conversion of methionine to cysteine. Previous stu

• CTGF is an established YAP TAZ target

  2022-04-02

  

  CTGF is an established YAP/TAZ target gene which plays a central role in tissue remodeling. Downregulation of CTGF mediates collagen loss in chronologically-aged human skin whereas persistent activation of CTGF can result in excessive deposition of collagen and fibrotic disorders [63]. The authors f

• An interference of fluorescence derived from biological samp

  2022-04-02

  

  An interference of fluorescence derived from biological samples is also an important Loratadine to be addressed in the fluorescent analysis for biological samples. Advanced glycation endproducts (AGEs) are representative endogenous fluorescent substances that are widely distributed in various organ

• Cephalexin receptor The inhibitory activities of new compoun

  2022-04-02

  

  The inhibitory activities of new compounds against P. aeruginosa were determined in both DTSB media supplemented with heme or free iron and LB media (Table 1). The MIC50 values of the compounds ranged from 42 to 260 μg/mL in DTSB medium and from 26 to 230 μg/mL in LB medium. Among these new inhibito

• Ellipticine Unfortunately the approved drugs suffer from

  2022-04-02

  

  Unfortunately, the approved drugs suffer from failure in many cases [5,6]. Several mutations occur in the binding site of NS3/4A protease, which affect drug binding and cause drug resistance [13]. It is a big challenge and needs more efforts to be done. This is the reason why research is still conce

• br Introduction Soluble guanylyl cyclase GC

  2022-04-02

  

  Introduction Soluble guanylyl cyclase (GC-1) maintains vascular function through the NO/GC-1/cGMP pathway [1,2] by catalyzing the conversion of GTP into cGMP (Fig. 1). The GC-1 heme prosthetic group binds NO with picomolar affinity, resulting in a 100- to 200-fold increase in catalytic activity.

• As a result of the capability of modulating the

  2022-04-02

  

  As a result of the capability of modulating the dynamic changes and rearrangement of cytoskeletons, the Rho GTPases, in which RhoA, Cdc42 and Rac1 are best-characterized, have been highlighted as significant contributors for orchestrating neuronal development (Duman et al., 2015, Heasman and Ridley,

• The gsnor ko plants contain

  2022-04-02

  

  The gsnor-ko plants contain elevated amount of low and high molecular weight S-nitrosothiols (SNO) indicating that GSNOR activity controls the level of both GSNO and indirectly protein-SNOs [13], [17], [18]. GSNOR deficiency has been shown to cause pleiotropic plant growth defects, impaired plant di

• GSK is a critical component of the Wnt signaling

  2022-04-02

  

  GSK-3 is a critical component of the Wnt signaling pathway. The Wnt/beta-catenin signal transduction pathway is important in normal growth and development and is also frequently dysregulated in cancer and other diseases. The Wnt/beta-catenin pathway is finely tuned by both positive and negative inte

• br Introduction br Mitochondrial dysfunction and cancer

  2022-04-02

  

  Introduction Mitochondrial dysfunction and cancer Lactate and succinate as oncometabolites Intracellular actions of lactate and succinate as tumor promoters Cell-surface receptors for lactate and succinate and their role in cancer GPR109A as the receptor for butyrate and β-hydroxybu

• Both GPR A and GPR are located

  2022-04-02

  

  Both GPR109A and GPR81 are located on chromosome 12q24 [3] and mediate anti-lipolytic effects through coupling to Gi-type G proteins [17]. It is important to note that with the recent deorphanization of these receptors, there has been a recommendation to the International Union of Basic and Clinical

• Due to the therapeutic potential of GlyT

  2022-04-01

  

  Due to the therapeutic potential of GlyT1 inhibitors, numerous drug screening campaigns have been started - and are still going on - which aimed at the identification of compounds with biological activity at or affinity for this drug target. For characterization of biological activity at GlyT1, tran

• The existence of EAAT subtypes raises obvious questions

  2022-04-01

  

  The existence of 5 EAAT subtypes raises obvious questions as to the cellular and anatomical distribution of the various transporters (for review, see Gegelashvili & Schousboe, 1998, Danbolt, 2001). While difference in techniques (i.e., protein vs. mRNA), reagents, and preparations (i.e., in vivo vs.

• The effect of the selected compounds on NF

  2022-04-01

  

  The effect of the selected compounds on NF-kB transrepression was assessed using the well-studied HeLa B2 cell line that expresses endogenous GR and NF-kB family members and responds properly to glucocorticoids and pro-inflammatory cytokines (such as TNF). Our data revealed that the two hit compound

• The first report about the activity of ANAM in CACs

  2022-04-01

  

  The first report about the activity of ANAM in CACs it is due to Garcia et al. [19] which treated 16 cancer patients with oral ANAM 50mg once daily vs placebo for 3days followed by a washout Conessine of 5–7days and then cross-over to the other group for 3 more days. It was described a weight gain

13752 records 415/917 page Previous Next First page 上5页 411412413414415 下5页 Last page